(Q38136576)

29 August 2017

New insights and modern treatment of AL amyloidosis (English)

1 reference

29 August 2017

Chakra P Chaulagain

1

1 reference

PubMed ID

24026941

29 August 2017

Raymond L Comenzo

series ordinal

2

1 reference

29 August 2017

1 December 2013

1 reference

Current hematologic malignancy reports

29 August 2017

1 reference

29 August 2017

8

1 reference

29 August 2017

4

1 reference

29 August 2017

291-298

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-013-0175-0

29 August 2017

0 references

cites work

The systemic amyloidoses

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Clinical proteomics for diagnosis and typing of systemic amyloidoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

21 January 2018

How I treat amyloidosis

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Primary systemic amyloidosis--a diagnostic primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Screening panels for detection of monoclonal gammopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Cellular response of cardiac fibroblasts to amyloidogenic light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

The challenge of systemic immunoglobulin light-chain amyloidosis (Al).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Amyloid diseases of the heart: current and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

CyBorD: stellar response rates in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0175-0

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

21 January 2018

1 reference

12 December 2020

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

12 December 2020

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

12 December 2020

Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis

1 reference

12 December 2020

Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis

1 reference

12 December 2020

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

1 reference

12 December 2020

Who knows how to treat systemic light chain amyloidosis?

1 reference

12 December 2020

[Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide].

1 reference

12 December 2020

Managing systemic light-chain amyloidosis

1 reference

12 December 2020

10.1007/S11899-013-0175-0

Identifiers

DOI

1 reference

PubMed ID

24026941

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

24026941